Fei Kuang1, Ziping Yan2, Jian Wang2, Ziyuan Rao2. 1. Department of Medical Imaging, The 174th Hospital of Chinese PLA, No 96, Wen Yuan Road, Xiamen, Fujian Province 361003, China. Electronic address: kuangfei_radiology@163.com. 2. Department of Medical Imaging, The 174th Hospital of Chinese PLA, No 96, Wen Yuan Road, Xiamen, Fujian Province 361003, China.
Abstract
PURPOSE: To investigate the value of apparent diffusion coefficient (ADC) to predict and monitor the therapy response for cervical cancer patients receiving concurrent radiochemotherapy, and to analyze the influence of different b-value combinations on ADC-based evaluation of treatment response. MATERIAL AND METHODS: Seventy-five cervical cancer patients treated with radiochemotherapy received conventional MRI and DWI prior to therapy, after 2 weeks of therapy, after four weeks of therapy and after therapy completion. Treatment response was classified as complete response (CR, n=35), partial response (PR, n=22) and stable disease (SD, n=18), which was determined according to final tumor size after 6 months of therapy completion. Dynamic changes of apparent diffusion coefficients (ADC) and tumor size in the three tumor groups were observed and compared. All the ADCs were calculated from b=0, 600s/mm(2) and b=0, 1000s/mm(2). RESULTS: The ADC increased percentage was higher in CR group than those in PR and SD groups after two weeks and four weeks of therapy, with significant differences in absolute ADCs between CR and PR, SD groups after therapy completion; the overall discriminatory capability for differentiation of CR and PR, SD groups was higher for high b-value combination (0, 1000s/mm(2)) than for low b-value combination (0, 600s/mm(2)). CONCLUSION: DWI can be used as a predictive and monitoring biomarker of treatment response to radiochemotherapy in patients with cervical cancer. High b-value combination may be more reliable to evaluate the treatment response for cervical cancer.
PURPOSE: To investigate the value of apparent diffusion coefficient (ADC) to predict and monitor the therapy response for cervical cancerpatients receiving concurrent radiochemotherapy, and to analyze the influence of different b-value combinations on ADC-based evaluation of treatment response. MATERIAL AND METHODS: Seventy-five cervical cancerpatients treated with radiochemotherapy received conventional MRI and DWI prior to therapy, after 2 weeks of therapy, after four weeks of therapy and after therapy completion. Treatment response was classified as complete response (CR, n=35), partial response (PR, n=22) and stable disease (SD, n=18), which was determined according to final tumor size after 6 months of therapy completion. Dynamic changes of apparent diffusion coefficients (ADC) and tumor size in the three tumor groups were observed and compared. All the ADCs were calculated from b=0, 600s/mm(2) and b=0, 1000s/mm(2). RESULTS: The ADC increased percentage was higher in CR group than those in PR and SD groups after two weeks and four weeks of therapy, with significant differences in absolute ADCs between CR and PR, SD groups after therapy completion; the overall discriminatory capability for differentiation of CR and PR, SD groups was higher for high b-value combination (0, 1000s/mm(2)) than for low b-value combination (0, 600s/mm(2)). CONCLUSION: DWI can be used as a predictive and monitoring biomarker of treatment response to radiochemotherapy in patients with cervical cancer. High b-value combination may be more reliable to evaluate the treatment response for cervical cancer.
Authors: Benjamin Lewis; Anamaria Guta; Stacie Mackey; H Michael Gach; Sasa Mutic; Olga Green; Taeho Kim Journal: J Appl Clin Med Phys Date: 2021-01-15 Impact factor: 2.102
Authors: A L Valentini; M Miccò; B Gui; M Giuliani; E Rodolfino; A M Telesca; T Pasciuto; A Testa; M A Gambacorta; G Zannoni; V Rufini; A Giordano; V Valentini; G Scambia; R Manfredi Journal: Eur Radiol Date: 2018-01-09 Impact factor: 5.315
Authors: Jennifer C Ho; Pamela K Allen; Priya R Bhosale; Gaiane M Rauch; Clifton D Fuller; Abdallah S R Mohamed; Michael Frumovitz; Anuja Jhingran; Ann H Klopp Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-17 Impact factor: 7.038
Authors: Jennifer C Ho; Penny Fang; Carlos E Cardenas; Abdallah S R Mohamed; Clifton D Fuller; Pamela K Allen; Priya R Bhosale; Michael M Frumovitz; Anuja Jhingran; Ann H Klopp Journal: Radiother Oncol Date: 2019-03-11 Impact factor: 6.280
Authors: Lei Tang; Yi Sui; Zheng Zhong; Frederick C Damen; Jian Li; Lin Shen; Yingshi Sun; Xiaohong Joe Zhou Journal: Magn Reson Med Date: 2017-06-22 Impact factor: 4.668